Abstract
Intravenous elotuzumab (Empliciti), a monoclonal antibody targeting the signalling lymphocytic activation molecule F7 (SLAMF7) glycoprotein, is approv......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
